dipyridamole has been researched along with Colitis, Granulomatous in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Poturoglu, S | 1 |
| Kaymakoglu, S | 1 |
| Gurel Polat, N | 1 |
| Ibrisim, D | 1 |
| Ahishali, E | 1 |
| Akyuz, F | 1 |
| Badur, S | 1 |
| Demir, K | 1 |
| Mungan, Z | 1 |
1 other study available for dipyridamole and Colitis, Granulomatous
| Article | Year |
|---|---|
A new agent for tumour necrosis factor-alpha inhibition: In vitro effects of dipyridamole in Crohn's disease.
Topics: Adolescent; Adult; Case-Control Studies; Crohn Disease; Dipyridamole; Dose-Response Relationship, Dr | 2009 |